Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Godaddy Inc (GDDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Godaddy Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.83 (market cap $39.89B), while Godaddy Inc trades at $89.89 (market cap $11.77B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.4× Godaddy Inc's market cap, and Godaddy Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GDDY | |
|---|---|---|
Market Cap | $39.89B | $11.77B |
Sector | Health | Technology |
52-Week High | $491.22 | $169.79 |
52-Week Low | $278.09 | $75.07 |
Enterprise Value | $38.15B | $14.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GoDaddy (GDDY) trades at $88.92, up 1.19% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a 63.77% gross margin and 17.32% net margin, though revenue growth has slowed. Analyst consensus is bullish with a $123 price target, but legal investigations pose near-term sentiment risks.
Outlook remains positive based on fundamentals and analyst ratings, but investors should weigh the high ROE and cash flow strength against slowing revenue growth and ongoing legal scrutiny. The stock offers value at a P/E of 14.09, yet legal overhang may limit upside until resolved.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →
